
KAPA
Healthcare · Biotechnology · $1.5M market cap
$0.4536-0.03 (-5.6%)Nov 13, 4:11 PM EST
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2026
EPS trend, 90 days to now · +8.3% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 2 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 13, 2026 | After the close | -0.63 | -0.59 | +6.3% |
| Aug 12, 2026 | After the close | -0.09 | -0.06 | +33.3% |
| Jun 3, 2026 | Time not confirmed | -0.49 | -0.56 | -14.3% |
| Mar 31, 2026 | After the close | 0.03 | -0.07 | -333.3% |
| Nov 14, 2025 | After the close | -0.07 | -0.07 | 0.0% |
| Aug 12, 2025 | After the close | -0.05 | -0.08 | -60.0% |
| Apr 15, 2025 | After the close | -0.02 | -0.03 | -50.0% |
| Feb 26, 2025 | Time not confirmed | -0.02 | -0.05 | -150.0% |
| Nov 14, 2024 | After the close | -0.02 | -0.10 | -400.0% |
| Aug 28, 2024 | Time not confirmed | — | -0.02 | — |
Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops immunotherapy and cell therapies for the treatment of cancer. The company offers therapeutics, including antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. It also develops ENV 105, an antibody therapeutic that is in a Phase 2 clinical trial for prostate cancer patients resistant…